Orexo Interim Report Q1 2022
Promising start to 2022 Q1 2022 highlights · Total net revenues of SEK 159.4 m (132.3) · EBITDA of SEK 2.8 m (-23.9) · Net earnings of SEK -23.6 m (-31.5) · US Pharma segment (ZUBSOLV® US) net revenues of SEK 139.1 m (126.8), in local currency USD 14.8 m (15.1), US Pharma EBIT of SEK 84.0 m (66.1) · Cash flow from operating activities of SEK -61.6 m (-47.8), cash balance of SEK 437.8 m (725.5) · Earnings per share before and after dilution amounted to -0.69 (-0.92) · Lead product ZUBSOLV® added to NY State Medicaid MAT Preferred Drug List as of March 22 · First